Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Systemic Amyloidosis Diagnosed in Formalin-Fixed Tissue

By LabMedica International staff writers
Posted on 30 Nov 2009
A specific and sensitive mass spectrometry-based method is being used for diagnosis and classification of amyloidosis in routine biopsy specimens, in a format that is rapid and readily applicable in a clinical setting. More...
Proteins are solubilized for mass spectrometric analysis of formalin-fixed paraffin-embedded (FFPE) tissue, the standard form of preserved patient tissue used in clinical pathology testing.

Expression Pathology, Inc. (EPI; Rockville, MD, USA) announced that the Mayo Clinic (Rochester, MN, USA) has licensed nonexclusive rights to Expression Pathology's Liquid Tissue methodology, which solubilizes proteins, for use in diagnosis of systemic amyloidosis in formalin-fixed tissue. The new test is being offered to patients worldwide through Mayo Medical Laboratories (Rochester, MN, USA), the Mayo Clinic's reference laboratory.

The Liquid Tissue-based method aids in treatment decisions as it exhibits greater sensitivity and specificity than the traditional immunohistochemistry (IHC)-based classification. In a case study of 56 FFPE cardiac biopsies involving amyloidosis, IHC was diagnostic in 19/52 cases and equivocal in 33/52 cases (4 cases no IHC). The mass spectrometry-based Liquid Tissue method identified the amyloidosis type in 53 of 56 cases studied.

Amyloidosis can be a localized or systemic disease, characterized by organ function impairment, sometimes as severe as cardiac and/or renal failure. Subtyping of cases is critical as management of the disease differs radically, from drug therapies to major organ transplants.

"Detailed mass spectrometry analysis of proteins related to specific disease conditions in FFPE tissue is opening huge opportunities in personalized medicine to relate those measurements to patient treatment decisions,” said Casey Eitner, president and CEO of Expression Pathology. "We are delighted that Mayo Clinic has applied our Liquid Tissue methodology to solve a difficult medical problem.”

The Mayo Clinic offers diagnostic tests to more than 5,000 healthcare institutions around the world through Mayo Medical Laboratories.

Expression Pathology Inc. developed techniques for discovery and quantitative analysis of protein biomarkers in FFPE tissue. The company's Director laser microdissection slides enable precise, rapid, automated collection of specific cellular features from tumor tissue.

Related Links:

Expression Pathology
Mayo Medical Laboratories




Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Sample Transportation System
Tempus1800 Necto
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.